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Abstract
Introduction The present study was carried out to assess
whether IgA-class antibodies against cyclic citrullinated
peptides (IgA anti-CCP) in recent-onset rheumatoid arthritis add
diagnostic and/or prognostic information to IgG anti-CCP
analysis.
Methods Serum samples were obtained from 228 patients with
recent-onset (<12 months) rheumatoid arthritis at the time of
inclusion in the Swedish TIRA cohort (Swedish Early
Intervention in Rheumatoid Arthritis). Sera from 72 of these
patients were also available at the 3-year follow-up. Disease
activity and functional ability measures (erythrocyte
sedimentation rate, serum C-reactive protein, 28-joint count
Disease Activity Score, physician's assessment of disease
activity, and the Swedish version of the Health Assessment
Questionnaire) were registered at inclusion and at regular
follow-ups during 3 years. An IgA anti-CCP assay was
developed based on the commercially available IgG-specific
enzyme immunoassay from EuroDiagnostica (Arnhem, the
Netherlands), replacing the detection antibody by an anti-
human-IgA antibody. A positive IgA anti-CCP test was defined
by the 99th percentile among healthy blood donors.
Results At baseline, a positive IgA anti-CCP test was observed
in 29% of the patient sera, all of which also tested positive for
IgG anti-CCP at a higher average level than sera containing IgG
anti-CCP alone. The IgA anti-CCP-positive patients had
significantly higher disease activity over time compared with the
IgA anti-CCP-negative patients. After considering the IgG anti-
CCP level, the disease activity also tended to be higher in the
IgA anti-CCP-positive cases – although this difference did not
reach statistical significance. The proportion of IgA anti-CCP-
positive patients was significantly larger among smokers than
among nonsmokers.
Conclusion Anti-CCP antibodies of the IgA class were found in
about one-third of patients with recent-onset rheumatoid
arthritis, all of whom also had IgG anti-CCP. The occurrence of
IgA-class antibodies was associated with smoking, and IgA anti-
CCP-positive patients had a more severe disease course over 3
years compared with IgA anti-CCP-negative cases. Although
IgA anti-CCP analysis does not seem to offer any diagnostic
information in addition to IgG anti-CCP analysis, further efforts
are justified to investigate the prognostic implications.
Introduction
Rheumatoid arthritis (RA) is a chronic disabling inflammatory
disease with increased risk of premature death, mainly due to
coronary vascular disease [1], but modern therapeutic strate-
gies in early RA have improved the prognosis considerably [2-
4]. Since, however, the clinical manifestations and conse-
quences of RA vary between individuals, as do the responses
to therapy, there is an urge to obtain reliable predictors of dis-
ease course/outcome and therapy response, in order to allow
rational individually tailored therapy regimens. Furthermore,
the high direct costs to society for biological agents place fur-
ther emphasis on the need for reliable predictors.
The discovery of anti-citrullinated peptide/protein antibodies
has had a large impact on routine serological testing [5,6].
Besides being highly specific diagnostic markers for RA, anti-Page 1 of 7
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of disease course and outcome [7-11]. The most widely used
and most extensively evaluated anti-citrullinated peptide/pro-
tein antibody assay is that developed by van Venrooij and col-
leagues; that is, IgG-class antibodies to anti-cyclic citrullinated
peptides (IgG anti-CCP) [6]. The second-generation anti-
CCP2 antibody tests have a diagnostic sensitivity for RA equal
to that of agglutinating rheumatoid factor (RF) and a disease
specificity of 90% to 99% [5,6]. Like RF, the presence of cir-
culating IgG anti-CCP has been shown to precede clinical
onset of disease by several years [9], indicating a pathoge-
netic role. The combination of HLA-DRB1 genes encoding the
shared epitope (SE) and cigarette smoking leads to a mark-
edly increased risk for anti-CCP-positive RA, implying a gene–
environment interaction [12-15].
Compared with RF, anti-CCP is a better prognostic marker of
an aggressive disease course with radiological progression
[7,8,10,11]. Despite the genetic connection, it seems that only
anti-CCP – not SE-carriage by itself – is associated with the
increased risk of radiological progression [11]. RF is known to
occur among all immunoglobulin isotypes. IgA-RF has been
stated of particular interest as a predictor of aggressive dis-
ease, at least when rabbit IgG is used as the source of antigen
for RF detection [16,17]. High circulating levels of RF and
immune complexes, in particular IgA-RF and IgA-containing
immune complexes, have also been shown to be associated
with systemic rheumatoid vasculitis [18,19], and high levels of
IgA-RF have been reported to be associated with poor
response to TNF inhibitors [20]. The aim of the present study
is to analyse to what extent IgA-class antibodies to anti-cyclic
citrullinated peptides (IgA anti-CCP) occur in recent-onset RA




Three hundred and twenty patients with recent-onset RA
(onset of joint swelling <12 months prior to inclusion) were
enrolled in the Swedish TIRA project (Swedish Early Interven-
tion in Rheumatoid Arthritis) during 27 months (1996 to 1998)
[8]. Of these patients, 97% fulfilled the 1987 revised Ameri-
can College of Rheumatology classification criteria [21], and
the remainder (n = 9) met the following criteria: morning stiff-
ness ≥ 60 minutes, symmetrical arthritis, and arthritis of hands
(wrists, metacarpophalangeal or proximal interphalangeal
joints) or feet (metatarsophalangeal joints). Serum samples
were available from 228 patients at the time of diagnosis, and
from 72 of these patients at the 3-year follow-up.
The patients were prescribed disease-modifying anti-rheu-
matic drugs (DMARDs) as judged appropriate by the treating
physicians, who were unaware of both the patients' IgG anti-
CCP status and IgA anti-CCP status. The prescription of tra-
ditional DMARDs (methotrexate, sulfasalazine, anti-malarial
drugs, gold, azthioprine) and/or TNF inhibitors was registered
at baseline and after 3, 6, 12, 24, and 36 months. On the same
occasions, serum C reactive protein, the 28-joint count Dis-
ease Activity Score [22] and the physician's global assess-
ment of disease activity were registered. Functional disability
was also assessed at baseline and after 12, 24 and 36 months
using the Swedish version of the Health Assessment Ques-
tionnaire [23].
The cigarette smoking status (current smoker (smoker at least
until 1 year before inclusion), previous smoker, or never
smoker) was registered at inclusion as described previously
[24]. The SE was assessed as previously described [25]. DNA
was available from 171 of the patients.
Autoantibody analyses
The second-generation IgG anti-CCP (RA immunoscan mark
2; EuroDiagnostica, Arnhem, the Netherlands) were analysed
as described previously [9], and a modification of this diagnos-
tic kit was used to analyse anti-CCP antibodies of the IgA
class. Patient sera were diluted 1:100 using the diluent pro-
vided with the kit. As a secondary antibody we used a horse-
radish peroxidase-conjugated polyclonal rabbit anti-human α-
chain antibody (DakoCytomation, Glostrup, Denmark), which
was diluted 1:2,000 with the kit diluent. A seven-step serial
dilution of a high-levelled IgA anti-CCP patient serum served
as the calibrator and the results were expressed as arbitrary
units (AU/ml).
Serum samples were analysed in duplicate and the cutoff limit
was set at 25 AU/ml based upon the 99th percentile of 80
blood donors (no differences were seen comparing female
and male blood donors). The intra-assay coefficient of variation
of the IgA anti-CCP assay was 13% based upon six sera ana-
lysed 13 times each, and the inter-assay coefficient of variation
(nine separate analyses) was 15%.
Particle agglutinating RF tests, which formed the basis for
classification as seropositive RA and seronegative RA,
respectively, were performed at the diagnostic laboratories
affiliated to the local hospitals participating in the study. Iso-
type-specific RF analyses (IgM and IgA) were carried out by
enzyme immunoassays as described previously [8].
Statistical analysis
Statistical analyses were performed using SPSS statistical
software (version 15.0; SPSS, Chicago, IL, USA). Spearman's
rho correlation coefficient was used to detect an association
between IgG anti-CCP and IgA-anti-CCP-levels. The Mann–
Whitney U test was used to evaluate the difference in IgG-anti-
CCP levels between IgA-positive sera and IgA-negative sera,
and to assess differences in antibody occurrence/antibody
levels between groups with different smoking and SE status.
Differences regarding disease activity measures and the
Health Assessment Questionnaire at baseline and over timePage 2 of 7
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ments. Changes in antibody levels over time were analysed by
Wilcoxon's signed-rank test.
Ethical considerations
The participating patients gave their written informed consent,
and the study protocol was approved by the regional ethics
committee in Linköping, Sweden.
Results
Patient characteristics in relation to their IgA anti-CCP status
are presented in Table 1.
IgA anti-CCP versus IgG anti-CCP results
Sixty-six of the 228 inclusion sera (29%) tested positive for
IgA anti-CCP, compared with 64% regarding IgG anti-CCP.
All sera testing positive for IgA anti-CCP were also positive in
the IgG assay, but only 47% of the sera testing positive for IgG
anti-CCP had anti-CCP antibodies of the IgA class. As illus-
trated in Figure 1, the levels of IgG anti-CCP and IgA anti-CCP
showed a high degree of correlation (Spearman's rho = 0.8, P
< 0.01). The IgA-positive sera had significantly higher levels of
IgG anti-CCP (P < 0.001) as compared with the IgG anti-
CCP-positive sera without concomitant IgA anti-CCP (Figure
2).
The status of IgA anti-CCP positivity remained essentially sta-
ble at the 3-year follow-up: 93% of patients were therefore
unchanged regarding IgA anti-CCP-positivity; one out of the
72 patients available for comparison between inclusion and
the 3-year follow-up (1.4%) had changed from negative to
positive, whereas four out of 72 patients (5.5%) had changed
from positive to negative. The baseline frequency of IgA anti-
CCP in these 72 sera did not differ significantly from the
remaining 156 patients (31% and 28%, respectively). Regard-
ing changes in the antibody level, eight of the IgA anti-CCP-
positive patients showed an increase >30% and seven
patients showed a decrease >30%. Overall, however, the
median level of IgA anti-CCP in the whole patient material
increased from 60 AU/ml to 81 AU/ml (P = 0.005).
IgA anti-CCP status versus disease course
Analysis of the IgA anti-CCP status at baseline in relation to
the number of fulfilled American College of Rheumatology
classification criteria at inclusion revealed that those patients
testing positive had a significantly higher median American
College of Rheumatology criterion count (4.73 versus 4.47, P
= 0.01). As shown in Figure 3, the proportion of IgA anti-CCP-
positive cases increased with an increasing count of fulfilled
American College of Rheumatology classification criteria.
The erythrocyte sedimentation rate, the 28-joint count Disease
Activity Score, and the Health Assessment Questionnaire
scores were consistently higher in patients with IgA anti-CCP
throughout the 3-year follow-up compared with those patients
testing negative (Figure 4a); by analysis of variance for
repeated measurements, this increase was statistically signifi-
cant for the erythrocyte sedimentation rate (P = 0.002) and
the 28-joint count Disease Activity Score (P = 0.0497). This
trend remained when comparing cases positive for IgG anti-
CCP alone with IgA anti-CCP-positive cases (Figure 4b), but
did not reach statistical significance by analysis of variance.
Table 1
Characteristics of the 228 rheumatoid arthritis patients
Total IgA anti-CCP-positive, IgG anti-CCP-
positive
IgA anti-CCP-negative, IgG anti-CCP-
positive
Number of patients 228 66 72
Mean age (years) 55 57 52
Number of women:men 158:70 48:18 46:26
Mean age (years) 54:59 55:62 51:53
Number of agglutinating rheumatoid factor-
positive
142 56 68
(%) 63 85 84
IgM-rheumatoid factor-positive (%) 74 98 96
Median level (U/ml) 114 247 184
IgA-rheumatoid factor-positive (%) 73 97 87
Median level (U/ml) 45 83 58
IgG anti-CCP-positive (%) 64 100 100
Median level among positive cases (U/ml) 520 1017 222
IgA anti-CCP, IgA-class antibodies against cyclic citrullinated peptides; IgG anti-CCP, IgG-class antibodies against cyclic citrullinated peptidesPage 3 of 7
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IgG anti-CCP (Figure 2), we made an attempt to evaluate the
possible influence of a high IgG anti-CCP level regarding dis-
ease progression in IgA anti-CCP-positive patients. Forty
patients, 20 IgA-positive and 20 IgA-negative, with pairwise
IgG anti-CCP, 80 to 1,045 U/ml; mean level, 501 U/ml). Com-
parison of these pairwise IgG-matched IgA-positive/IgA-nega-
tive cases revealed the same tendency; that is, IgA anti-CCP-
positive patients had a more aggressive disease course over
3 years – although the differences did not reach statistical sig-
nificance (Figure 4c).
The higher preparedness to prescribe DMARDs to IgG anti-
CCP-positive patients as compared with anti-CCP-negative
cases in the present cohort [8] was not further enhanced in
the IgA anti-CCP-positive cases (Figure 5). We had no access
to radiographic follow-up, but at baseline the presence of typ-
ical X-ray findings in hands and feet were comparable
between anti-CCP-positive and anti-CCP-negative patients
(14% versus 12%) for both IgA-class and IgG-class
antibodies.
IgA anti-CCP status and IgG anti-CCP status versus 
smoking and shared epitope
Forty-three per cent of the current smokers were IgA anti-
CCP-positive (n = 40), compared with 37% among previous
smokers (n = 38) and 25% among never smokers (n = 150).
The difference between current smokers and never smokers
was significant regarding the proportion of patients testing
positive for IgA anti-CCP (P = 0.027), but not regarding the
mean antibody levels of IgA anti-CCP-positive patients. The
corresponding difference regarding smoking and IgG anti-
CCP status did not reach statistical significance.
When subgrouping the patients based on SE status (double,
single, or no SE copies), the presence of IgG anti-CCP
Figure 1
Correlation of IgA-class and IgG-class antibodies against cyclic citrulli-nated peptidesl tion of IgA-cla s and IgG-class antibodies against cycl c cit
rullinated peptides. Correlation between IgG-class antibodies against 
cyclic citrullinated peptides (IgG anti-CCP) levels and IgA-class anti-
bodies against cyclic citrullinated peptides (IgA anti-CCP) levels in 215 
early rheumatoid arthritis sera analysed at inclusion.
Figure 2
IgG-class antibody levels (median/75-percentiles) in IgG-positive patients with and without IgA-cl ss antibodies aga st cyclic c trulli-n ed peptidess antibody levels (median/75-p rcentiles) in IgG-positive 
patients with and without IgA-class antibodies against cyclic cit-
rullinated peptides. Box plots illustrating the median IgG-class anti-
bodies against cyclic citrullinated peptides (IgG anti-CCP) levels as 
well as the 75th percentiles and total ranges among the IgG-positive 
patients with positive IgA-class antibodies against cyclic citrullinated 
peptides (IgA anti-CCP) tests.
Figure 3
IgA-class antibody status in relation to baseline number of fulfilled American College of Rheumatology criterial ss antibody status in relation o baseli e number of fulfilled 
American College of Rheumatology criteria. Proportion of IgA-class 
antibodies against cyclic citrullinated peptides (IgA anti-CCP)-positive 
patients in relation to the number of American College of Rheumatology 
(ACR) criteria fulfilled at inclusion.Page 4 of 7
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manner. In the group with two SE copies, 95% were IgG anti-
CCP-positive – compared with 70% in the group with one
copy and 33% in the group without a SE. A much weaker
(nonsignificant) trend was recorded regarding IgA anti-CCP
status versus SE status (39% in SE+/+, 27% in SE+/-, and 21%
in SE-/-).
Discussion
Analysis of IgA-class autoantibodies is well established
regarding a few disease states, most notably antibodies
against endomysium and tissue transglutaminase in coeliac
disease [26,27]. Anti-neutrophil cytoplasmic antibodies of the
IgA class have been reported to occur in ulcerative colitis,
autoimmune liver diseases, Henoch–Shönlein's purpura, and
neutrophilic dermatoses [28-31], and RF of the IgA class has
been claimed to be of clinical interest in RA [16-20].
In a study by Verpoort and colleagues in Leiden, IgA anti-CCP
antibodies were analysed in early arthritis patients testing pos-
itive for IgG anti-CCP [32]. In the present study on early RA
we found anti-CCP antibodies of the IgA isotype in 29% of the
patients in total, and in 47% of the patients testing positive for
anti-CCP antibodies of the IgG class. The reason for the
slightly lower proportion of IgA anti-CCP-positive patients in
our study compared with the Leiden group may be the tough
cutoff limit applied in the present study. The finding that a
positive test in the IgA assay was restricted to patients with
IgG anti-CCP antibodies, however, confirms the findings of
Verpoort and colleagues [32]. In a study by Anzilotti and col-
leagues, antibodies of the IgA class reacting with a citrulli-
Figure 4
Disease activity and functional ability measurese activity and function l ability measures. Course of the erythrocyte sedimentation rate (ESR), the 28-joint count Disease Activity Score 
(DAS28) and the Health Assessment Questionnaire (HAQ) over 3 years. (a) All patients. (b) IgG-class antibodies against cyclic citrullinated pep-
tides (IgG anti-CCP)-positive RA patients. (c) 20 IgA-class antibodies against cyclic citrullinated peptides (IgA anti-CCP)-positive patients and 20 
IgA anti-CCP-negative patients, with pairwise comparable IgG levels. *P < 0.05.Page 5 of 7
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did not have detectable IgG anti-citrullinated viral peptide anti-
bodies [33].
We and other workers have shown that the presence of IgG
anti-CCP is related to a more severe disease course with
poorer outcome compared with patients testing negative for
IgG anti-CCP [7,8,10]. Similarly, in the present study, patients
testing positive for IgA anti-CCP had significantly higher dis-
ease activity over 3 years of prospective follow-up compared
with those patients testing negative. This may, at least in part,
be explained by the concomitant presence of IgG anti-CCP
antibodies. The tendency to higher disease activity in the IgA
anti-CCP-positive/IgG anti-CCP-positive patients as com-
pared with those with IgG anti-CCP alone could also hypo-
thetically have been related to the higher baseline levels of IgG
anti-CCP, since previous studies indicate that high levels of
IgG anti-CCP indicate a more severe disease [34]. We found,
however, that IgA-anti-CCP-positive patients tended to have a
more severe disease course over 3 years as compared with
IgA-negative cases with the same baseline levels of IgG anti-
CCP. This observation, suggesting that IgA anti-CCP may
possibly have an even better predictive potential than IgG anti-
CCP regarding disease course, calls for further prospective
studies, including radiographic evaluation, in larger patient
materials. Similar to the IgG anti-CCP status at baseline and
3-year follow-up [8], the presence or absence of IgA anti-CCP
at baseline usually remained after 3 years. Contrary to IgG-
class antibody levels in serum, however, the average IgA anti-
CCP level had not decreased 3 years after diagnosis and insti-
tuted DMARD therapy – but rather, on the contrary, had
increased. We think this observation is interesting, but it needs
further scrutiny in future studies before any far-reaching con-
clusions can be made.
Klareskog and colleagues have proposed the hypothesis that
cigarette smoking acts as a local airway trigger of excessive
citrullination leading to immunisation in SE-positive individuals
[12]. SE carriage is not, however, an absolute prerequisite to
develop immunity to citrullinated antigens. In the present
study, 95% and 70% of the patients with double SE copies
and single SE copies, respectively, were IgG anti-CCP-posi-
tive, but as many as 33% were positive in the group without
SE. The corresponding figures regarding IgA anti-CCP anti-
bodies were 39%, 27% and 21%. Despite the low association
with SE, the occurrence of IgA-anti CCP significantly corre-
lated to smoking, which again corroborates recent findings by
Verpoort and colleagues [35]. We think the IgA response to
citrullinated antigens attracts special interest with regard to
mucosal triggers, and we propose that IgA anti-CCP of
mucosal origin should be analysed in future studies.
Conclusion
IgA anti-CCP analysis does not appear to add a diagnostic
benefit to IgG anti-CCP analysis alone, but the presence of
IgA-class antibodies may predict a more severe disease
course in early RA. Further studies are justified to shed more
light on this question.
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